Given a context passage, generate a question from the passage such that its answer is shortest continous span from the passage.

Q: In this phase 2 proof-of-concept study we examined the safety and efficacy of selexipag, an orally available, selective prostacyclin receptor (IP receptor) agonist, as a treatment for pulmonary arterial hypertension (PAH). 43 adult patients with symptomatic PAH (receiving stable endothelin receptor antagonist and/or a phosphodiesterase type-5 inhibitor therapy) were randomised three to one to receive either selexipag or placebo. Dosage was up-titrated in 200-g increments from 200 g twice daily on day 1 to the maximum tolerated dose by day 35 (maximum allowed dose of 800 g twice daily). Change in pulmonary vascular resistance at week 17 expressed as a percentage of the baseline value was the primary efficacy end-point, and was analysed in the per protocol set first and then in the all-treated set to assess robustness of results. A statistically significant 30.3% reduction in geometric mean pulmonary vascular resistance was observed after 17 weeks' treatment with selexipag compared with placebo (95% confidence limits -44.7- -12.2; p=0.0045, Wilcoxon rank sum test). This was supported by a similar result from the all-treated set. Selexipag was well tolerated with a safety profile in line with the expected pharmacological effect. Our results encourage the further investigation of selexipag for the treatment of PAH.

A: Selexipag is used for which disease?
****
Q: When you make a mistake, big or small, cherish it like it's the most precious thing in the world, because in some ways, it is. Most of us feel bad when we make mistakes, beat ourselves up about it, feel like failures, get mad at ourselves. And that's only natural. Most of us have been taught from a young age that mistakes are bad, and we should try to avoid mistakes. We've been scolded when we make mistakes--at home, school and work. Maybe not always, but probably enough times to make feeling bad about mistakes an unconscious reaction. Yet without mistakes, we could not learn or grow. If you think about it that way, mistakes should be cherished and celebrated for being one of the most amazing things in the world. They make learning possible; they make growth and improvement possible. By trial and error--trying things, making mistakes, and learning from those mistakes--we have figured out how to make electric light, to paint the ceiling of the Sistine Chapel, to fly. Mistakes make walking possible for the smallest _ , make speech possible, and make works of genius possible. Think about how we learn:We don't just consume information about something and instantly know it or know how to do it. You don't just read about painting,or writing,or computer programming,or baking, or playing the piano, and know how to do them right away. Instead, you get information about something, from reading or from another person or from observing usually...then you construct a model in your mind...then you test it out by trying it in the real world...then you make mistakes...then you revise the model based on the results of your real world experimentation...and repeat, making mistakes, learning from those mistakes, until you've pretty much learned how to do something. That's how we learn as babies and toddlers, and how we learn as adults. Mistakes are how we learn to do something new--because if you succeed at something, it's probably something you already knew how to do. You haven't really grown much from that success--at most it's the last step on your journey, not the whole journey. Most of the journey is made up of mistakes, if it's a good journey. So if you value learning,if you value growing and improving,then you should value mistakes. They are amazing things that make a world of brilliance possible.

A: What is the best title of this passage?
****
Q: In a double-blind placebo-controlled prospective clinical trial we studied the efficacy and safety of the benzodiazepine antagonist, flumazenil. In 23 patients admitted to the Intensive Care Unit with coma due to overdose with benzodiazepines or other sedatives, flumazenil i.v. (up to 2 mg or placebo) was given. In 13 patients given flumazenil the Glasgow Coma Scale (GCS) increased significantly from 4.9 to 7.8 (p less than 0.05). Six of these 13 patients, including mainly benzodiazepine mono-intoxications, needed only one series of injections (up to 1.0 mg flumazenil); the GCS increased thereby from 4.5 to 10.7 within a maximum of 5 min (p less than 0.01). In the remaining 7 patients, needing two series of injections of flumazenil (up to 2.0 mg), GCS did not rise significantly and coma was related to intoxications with nonbenzodiazepine sedatives, flunitrazepam and in one patient, encephalitis. In the 10 patients receiving placebo, the GCS did not change. A significant increase in the GCS from 5.5 to 10.8 (p less than 0.001) was, however, observed when flumazenil (up to 1.0 mg) was given after placebo. In patients with EEG monitoring the changes in waveform pattern paralleled the clinical response. Effects could be detected within 1-2 min after flumazenil injection and lasted up to 45 min. There were no adverse reactions or benzodiazepine withdrawal symptoms. We conclude that flumazenil is an effective and safe drug in the treatment of benzodiazepine overdose. The use of flumazenil is of diagnostic value in mixed-drug intoxications or coma of unknown origin and is of therapeutic importance for reversal of benzodiazepine intoxications.

A:
Which drug should be used as an antidote in benzodiazepine overdose?
****